It is questionable whether patients with other targetable/driver mutations, such as ROS1 or RET, should be treated with NA ICI-chemo, based on data showing the limited efficacy of immunotherapy in patients with advanced lung cancer who have these mutations [42]. Here, RET is linked to lung carcinoma.